CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 300 enrolled
Drug / intervention
Sugammadex +1 moredrug
Likely dose
Sugammadex 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01101139
NCT01101139Phase 4Completed
CompareCT.gov

Small Dose of Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery (TOF 0.9)

Technical University of Munich·interventional·Posted Apr 9, 2010·Updated Dec 17, 2012

In Brief

A Phase 4 clinical trial evaluating Sugammadex and Placebo for Neuromuscular Blockade. Completed, enrolled 300 participants across 1 site.

Detailed Summary

This study is designed to investigate, whether Sugammadex improves muscle function after standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 9, 2010
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.2 years ago

Interventions

Sugammadexdrug

Sugammadex (single intravenous injection 0.25 mg/kg)

Placebodrug

Placebo: single intravenous injection Saline 0.9%